Global capital is making significant bets on brain-computer interface (BCI) technology, accelerating its industrialization cycle. The secondary market valuation of Elon Musk's Neuralink has surged to between $29 billion and $42 billion, a nearly fourfold increase from last year's $9 billion valuation, with some capital even offering acquisition bids approaching $60 billion. This collective optimism reflects a strong belief in the long-term growth potential of BCI.

This valuation surge is underpinned by three key drivers. First, the potential IPO of SpaceX has boosted the premium on Musk's assets, with capital chasing his frontier technology ventures. Second, clinical progress has exceeded expectations, with 21 patients already having received brain implants and a target of 1,000 implant procedures by the end of 2026, signaling the transition to mass production. Third, BCI is being defined as the critical nexus connecting biological brains with AI and humanoid robots, positioning it as foundational infrastructure for the next generation of intelligent industries.

The global enthusiasm has directly transferred to the A-share market. When news of Neuralink's mass production plans broke earlier this year, the BCI sector index surged over 10% in a single day, with multiple stocks hitting their daily limit-up. The domestic BCI industry in China has concurrently entered a golden development phase characterized by parallel progress in clinical translation, equipment manufacturing, and real-world application.

Key Investment Segments Within the Domestic Industry

The domestic industry has formed clear, stratified investment segments. Downstream, clinical hospitals are the conduits for implant surgery translation. Midstream, rehabilitation equipment is achieving commercialization within hospital settings. Upstream, components like electrodes, precision parts, and signal chips are essential consumables across the entire sector. This complete industrial chain is now experiencing a window for both valuation re-rating and earnings growth.

Downstream Clinical Translation Leaders: The Core Platforms for Surgical Implementation

Sanbo Brain Hospital Co., Ltd. (SZSE: 301293) stands as the absolute leader in China's BCI clinical ecosystem. It is the only A-share company that has integrated a complete closed loop encompassing university R&D, equipment manufacturers, clinical surgery, and industrial capital. Academically, it is deeply partnered with Tsinghua University, having invested a cumulative 15 million yuan over three years to co-establish a joint research center for BCI precision medicine. The partners aim to jointly establish a Beijing municipal key laboratory by 2026. Their collaborative "Beinao No. 1" project successfully completed China's first clinical BCI implant surgery, granting the company mastery over the core clinical surgical capabilities for invasive BCI.

On the industrial cooperation front, the company collaborates with Borui Kang for equipment and clinical synergy, where Borui Kang provides hardware and Sanbo handles implant surgeries and post-operative clinical validation. It also partners with Zhonghua BCI and Mailian Medical for non-invasive rehabilitation scenarios. Furthermore, it collaborates with Xuanwu Hospital, Tiantan Hospital, and the Beijing Institute for Brain Science to build a national-level brain science cooperation platform. On the capital side, through its own fund, it led a nearly 100 million yuan Series A round in Lingxi Cloud, a BCI data platform, and has established three dedicated brain science funds. It also spearheads the establishment of a national BCI clinical application scenario platform, solidifying its position at the core entry point for domestic invasive BCI clinical translation and positioning it to fully benefit from the incremental opportunities arising from the clinical deployment of implantable devices.

Innovation Medical Management Co., Ltd. (SZSE: 002173) is a rare A-share company simultaneously advancing both invasive and non-invasive rehabilitation pathways. It holds a 68.36% controlling stake in Borin BCI, a leading domestic invasive BCI firm. Its core products, the AC5 home-based non-invasive rehabilitation system and the HC2 hand exoskeleton, have already achieved batch production and market sales, targeting stroke and motor impairment rehabilitation scenarios, with products included in multiple local medical insurance rehabilitation fee schedules.

Its invasive AM5 implantable electrode device has entered the multi-center clinical trial stage and is expected to obtain Class III medical device registration and be included in surgical consumable medical insurance coverage within the year. This dual-track approach—hospital-based rehabilitation plus home-use devices—opens significant commercial space, offering notable short-term earnings potential.

Midstream Rehabilitation Equipment and Algorithm Providers: Early Commercialization in Hospitals

Xiangyu Medical (SHSE: 688626) is a leader in non-invasive BCI rehabilitation equipment, with a full-chain layout covering self-developed chips, algorithms, and electrodes. It holds medical device registration certificates for two EEG acquisition devices and has over ten BCI rehabilitation devices in the registration application stage. Its products are deployed in over 800 tertiary hospitals and more than 600 specialized BCI rehabilitation centers nationwide, with its long-accumulated hospital channels forming a formidable competitive moat. The company has established an independent BCI division, and its rehabilitation equipment maintains high gross margins. The revenue contribution from its BCI-related business continues to increase, with non-invasive devices serving as the main driver for near-term commercialization and providing stable earnings growth.

Weisi Medical (SHSE: 688580) is a core manufacturer of non-invasive EEG rehabilitation equipment. It integrates EEG acquisition with transcranial magnetic stimulation technology to build a closed-loop rehabilitation system. Its self-developed 256-channel high-precision EEG acquisition device fits within hospital rehabilitation pricing systems, and its products are used in neurology rehabilitation departments of numerous tertiary hospitals across China, with related BCI rehabilitation services covered by medical insurance in many regions. The company's BCI business revenue share is steadily rising. With a rich patent portfolio, it leverages its mature rehabilitation equipment distribution channels to rapidly penetrate the BCI rehabilitation sector, benefiting from sustained growth in hospital equipment procurement demand.

iFlytek Co., Ltd. (SZSE: 002230) is a key player in BCI algorithms. Leveraging its self-developed large language model, it optimizes AI decoding capabilities for EEG signals, achieving high-precision intention recognition and neural signal translation, thereby bridging the interaction channel between BCI and general AI. Its algorithmic solutions are compatible with both non-invasive and invasive BCI hardware across categories, applicable in medical rehabilitation, human-computer interaction, and assisted driving scenarios. The technical barriers of its AI large model are difficult to replicate, positioning it to benefit long-term from the wave of BCI intelligence upgrades.

Upstream Core Hardware Suppliers: Essential Components with Strong Long-Term Certainty

Meihao Medical (SZSE: 301363) is a scarce mass-production leader for precision components used in invasive BCI implants. Building on over a decade of expertise in cochlear implant precision machining, its processes can be directly transferred to the manufacturing of brain implants and biocompatible precision parts. It simultaneously covers invasive, semi-invasive, and non-invasive technical routes, providing custom supply for several leading domestic BCI companies and participating in setting BCI industry standards. Regardless of which technical route ultimately dominates the industry, implantable precision components will remain essential consumables. With a diversified customer base and sustained order flow, the company possesses robust growth attributes capable of weathering industry cycles.

Hanwei Technology Group Co., Ltd. (SZSE: 300007) is a core supplier of flexible neural electrodes. A subsidiary project won a special grant from the Ministry of Industry and Information Technology for key BCI components. Flexible electrodes are a universal core component for EEG signal acquisition, required for both non-invasive headbands and invasive implant devices. The company's mature sensor technology supplies dozens of midstream equipment manufacturers. The upstream component sector is insulated from the impact of technological iteration by any single equipment maker and stands to benefit long-term from the scaling production of BCI devices.

Chengdu Sino Microelectronics Technology Co., Ltd. (SHSE: 688709) is engaged in R&D for dedicated chips used in neural signal acquisition. These chips are core components for signal decoding and data processing in BCI devices. High-precision analog chips can significantly improve EEG signal recognition accuracy and are compatible with both invasive implant devices and non-invasive rehabilitation equipment. The upstream chip segment offers vast potential for import substitution, and the scaling production of downstream equipment directly drives chip procurement demand.

Consumer-Grade BCI Specialists: Tapping the Home-Use Market

Jiahe Intelligent Audio (SZSE: 300793) is developing consumer-grade non-invasive BCI interaction terminals. It holds stakes in a BCI chip company and possesses patents related to EEG wave acquisition, having already achieved batch production for overseas consumer-grade EEG headphones through OEM. Differentiating itself from the in-hospital medical track, the company focuses on consumer scenarios like home relaxation, sleep monitoring, and intention-based interaction, opening a completely new incremental space in the civilian market. Its consumer electronics production capacity and channel advantages empower the rapid scaling of its BCI terminals.

Long-Term Industry Development Thesis

Neuralink's soaring valuation confirms global capital's long-term bullish outlook on the BCI sector. The domestic industry in China has moved beyond the early conceptual phase and entered the first year of industrialization, driven by the combined catalysts of clinical implementation, equipment mass production, and medical insurance integration. The industry chain presents a clear, layered investment logic. Downstream clinical hospitals control the core scenarios for invasive device deployment. Midstream rehabilitation equipment offers the fastest near-term earnings realization. Upstream electrodes, precision components, and dedicated chips, as essential consumables across the entire sector, possess long-term, stable growth value. Companies across the full industrial chain are simultaneously entering a cycle of sustained valuation and order growth.